What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis

Autor: Vale, C L, Fisher, D J, White, I R, Carpenter, J R, Burdett, S, Clarke, N W, Fizazi, K, Gravis, G, James, N D, Mason, Malcolm, Parmar, M K B, Rydzewska, L H, Sweeney, C J, Spears, M R, Sydes, M R, Tierney, J F

Background\ud \ud Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetax

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::f940240c1847bb88f25a770ac4b0af4e
https://orca.cardiff.ac.uk/id/eprint/112173/9/mdy071.pdf

What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis

Autor: Vale, C. L., Fisher, D. J., Carpenter, J., White, I. R., Burdett, S., Clarke, N. W., Fizazi, K., Gwenaelle Gravis, James, N. D., Mason, M. D., Parmar, M. K., Rydzewska, L. H., Sweeney, C. J., Spears, M. R., Sydes, M. R., Tierney, J. F.

Publikováno v: Web of Science

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b52d0a1719d10c23c2e5f8f679dd5b87
https://publons.com/publon/9705578/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.

Autor: Vale CL; MRC Clinical Trials Unit at UCL, London. Electronic address: claire.vale@ucl.ac.uk., Fisher DJ; MRC Clinical Trials Unit at UCL, London., White IR; MRC Clinical Trials Unit at UCL, London., Carpenter JR; MRC Clinical Trials Unit at UCL, London., Burdett S; MRC Clinical Trials Unit at UCL, London., Clarke NW; Salford Royal NHS Foundation Trust, Salford, UK., Fizazi K; Gustave-Roussy, University of Paris Sud, Villejuif., Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France., James ND; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham; Queen Elizabeth Hospital, Birmingham., Mason MD; School of Medicine, Cardiff University, Cardiff, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, London., Rydzewska LH; MRC Clinical Trials Unit at UCL, London., Sweeney CJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Spears MR; MRC Clinical Trials Unit at UCL, London., Sydes MR; MRC Clinical Trials Unit at UCL, London., Tierney JF; MRC Clinical Trials Unit at UCL, London.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 May 01; Vol. 29 (5), pp. 1249-1257.